News & Events

Learn about what's new with CMC Biologics

World ADC Conference, November 12 - 14, 2018, San Diego, CA

Events

Join us at World ADC Conference in San Diego, CA.

We'll be at Booth #29. Let's talk about how our Bioreactor 6PackTM facilities could be the ideal solution for your production needs. Email us at info@agcbio.com to set up a meeting.

Bio-Europe, November 5 - 7, 2018, Copenhagen, Denmark

Events

Want to meet  us in Copenhagen for Bio-Europe? 

We'll be at Booth #103. Stop by to discuss how our Bioreactor 6PackTM facilities are the ideal solution for your production needs.

Outsourced Pharma, October 29-30, 2018, San Francisco, CA

Events

Will you be at Outsourced Pharma in San Francisco? 

Stop by Booth #25 to see how our Bioreactor 6PackTM facilities are the ideal solution for your production needs. Email us at info@agcbio.com to schedule a meeting.

European Antibody Congress, October 29-31, 2018, Basel, Switzerland

Events

Headed to Basel? Stop by Booth #54 to see how our Bioreactor 6PackTM facilities are the ideal solution for your production needs.

Email us at info@agcbio.com to schedule a meeting during the conference. 

BioProduction 2018, October 9 - 10, Dublin, Ireland

Events

Meet us in Dublin at BioProduction 2018.

AGC Biologics will be at Booth #36 ready to  discuss your current and upcoming project needs and how we can offer innovative solutions to help meet your goals.

BioJapan 2018 October 10 - 12, 2018, Yokohama, Japan

Events

We hope to see you at BioJapan in Yokohama. 

Visit AGC Biologics at Booth #C-03.

Stop by see how our Bioreactor 6PackTM facilities are the ideal solution for your production needs.

AGC Biologics Adds Mammalian Production Capacity in Japan

News

New facility will include comprehensive mammalian process development and manufacturing capabilities

BOTHELL, WA and CHIBA, JAPAN; Sept 20, 2018 ─ AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other
types of therapeutic proteins.

Follow Us
Join us on LinkedIn Follow us on Twitter